Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Teva
Fish and Richardson
US Army
Julphar
Express Scripts
Dow
UBS
QuintilesIMS

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202230

« Back to Dashboard

NDA 202230 describes LOSARTAN POTASSIUM, which is a drug marketed by Alembic Pharms Ltd, Apotex Corp, Aurobindo Pharma, Cadista Pharms, Hetero Labs Ltd V, Ipca Labs Ltd, Lupin Ltd, Macleods Pharms Ltd, Mylan, Prinston Inc, Sandoz, Teva, Torrent Pharms, Unichem Labs Ltd, Upsher-smith Labs, Viva Hlthcare, Vivimed Global, Watson Labs, West-ward Pharms Int, Zydus Pharms Usa Inc, Apotex, and Teva Pharms, and is included in thirty-six NDAs. It is available from sixty-six suppliers. Additional details are available on the LOSARTAN POTASSIUM profile page.

The generic ingredient in LOSARTAN POTASSIUM is hydrochlorothiazide; losartan potassium. There are thirty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; losartan potassium profile page.
Summary for 202230
Tradename:LOSARTAN POTASSIUM
Applicant:Macleods Pharms Ltd
Ingredient:losartan potassium
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 202230
Medical Subject Heading (MeSH) Categories for 202230
Suppliers and Packaging for NDA: 202230
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LOSARTAN POTASSIUM losartan potassium TABLET;ORAL 202230 ANDA Macleods Pharmaceuticals Limited 33342-044 N 33342-044-07
LOSARTAN POTASSIUM losartan potassium TABLET;ORAL 202230 ANDA Macleods Pharmaceuticals Limited 33342-044 N 33342-044-10

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG
Approval Date:May 30, 2012TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength50MG
Approval Date:May 30, 2012TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:May 30, 2012TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Merck
UBS
Dow
Cerilliant
Julphar
McKinsey
McKesson
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.